Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic effects of growth hormone in children with Kabuki syndrome
NL-OMON20379Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of somatropin in Kabuki syndrome and growth disorder, sponsored by Maastricht University Medical Center+. Primary endpoints: Increase in total energy expenditure after 6 weeks, Relationship between short-term change in total energy expenditure and long-term growth response and 3 more. Started Apr 2013; status: recruiting.
02
Drugs
somatropin
03
Conditions
Kabuki syndromegrowth disorder
Beyond the preview
Go deeper on NL-OMON20379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20379.